Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| AUTOLUS THERAPEUTICS | 5 | - | -10,43 % | ||
| ALUMIS | 4 | 2 | -5,62 % | ||
| ROCKET PHARMACEUTICALS | 4 | - | -14,45 % | ||
| PUMA BIOTECHNOLOGY | 3 | - | -2,11 % | ||
| ARCUTIS BIOTHERAPEUTICS | 3 | - | -5,23 % | ||
| KYMERA THERAPEUTICS | 2 | 6 | -2,82 % | ||
| SYNDAX PHARMACEUTICALS | 2 | 1 | 0,00 % | ||
| BIOCRYST PHARMACEUTICALS | 2 | - | +3,20 % | ||
| 4D MOLECULAR THERAPEUTICS | 2 | - | -8,53 % | ||
| MONTE ROSA THERAPEUTICS | 1 | 21 | -1,98 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:54 | Alumis reports Phase 3 psoriasis trial results for envudeucitinib | 1 | Investing.com | ||
| 18:46 | Alumis meldet überzeugende Phase-3-Ergebnisse für Psoriasis-Wirkstoff Envudeucitinib | 1 | Investing.com Deutsch | ||
| 18:36 | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | 1 | GlobeNewswire (USA) | ||
| 17:48 | Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis | 210 | AFX News | PARIS (dpa-AFX) - Sanofi SA (SNY, SNYNF,SAN.PA) announced encouraging results from three Phase 3 clinical trials-COAST 1, COAST 2, and SHORE-evaluating amlitelimab, a fully human non-T cell... ► Artikel lesen | |
| 16:34 | Sanofi meldet positive Phase-3-Daten für Medikament gegen atopische Dermatitis | 6 | Investing.com Deutsch | ||
| 16:34 | Arcutis: Studiendaten belegen Wirksamkeit von Roflumilast-Creme bei Säuglingen mit Neurodermitis | 3 | Investing.com Deutsch | ||
| 16:18 | Sanofi reports positive phase 3 data for atopic dermatitis drug | 6 | Investing.com | ||
| 16:18 | Arcutis presents trial data on roflumilast cream for infants | 2 | Investing.com | ||
| 16:06 | Sanofi: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session | 413 | GlobeNewswire (Europe) | AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed... ► Artikel lesen | |
| 16:06 | Kymera Therapeutics, Inc.: Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 16:06 | Arcutis Biotherapeutics, Inc.: Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 15:14 | Protagonist Therapeutics: Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology Annual Meeting | 563 | ACCESS Newswire | One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults further... ► Artikel lesen | |
| 10:30 | BioNTech: Was bedeutet der Gründer-Ausstieg für Ihr Depot? | Hebelschein-Spekulant | |||
| 06:10 | BioCryst strebt Milliardenumsatz an und stärkt HAE-Portfolio mit Navenibart | 6 | Investing.com Deutsch | ||
| 06:10 | Puma Biotechnology Q4 2025: NERLYNX-Umsatz steigt sequenziell um 15 % | 1 | Investing.com Deutsch | ||
| 06:10 | Puma Biotechnology meldet starkes Q4-Ergebnis, doch Aktie fällt wegen operativer Bedenken | 2 | Investing.com Deutsch | ||
| 04:06 | BioCryst 2025 slides: path to $1B revenue, Navenibart expands portfolio | 1 | Investing.com | ||
| 04:06 | Puma Biotechnology Q4 2025 slides: NERLYNX revenue rises 15% sequentially | 1 | Investing.com | ||
| 01:18 | Cathie Wood's ARK sells Nvidia stock, buys Arcturus Therapeutics | 27 | Investing.com | ||
| 00:26 | CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress | 6 | Insider Monkey |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.